Biosimilars in psoriasis: What can we expect?;Biosimilars bei Psoriasis: Was können wir erwarten?

JDDG - Journal of the German Society of Dermatology

Volumn 12, Issue 4, 2014, Pages 306-314

  Radtke, Marc Alexander ^a,b   Augustin, Matthias ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Dermatologie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BIOSIMILAR AGENT; ETANERCEPT; DERMATOLOGICAL AGENT; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; BIOEQUIVALENCE; DERMATOLOGY; DRUG EFFICACY; DRUG QUALITY; DRUG SAFETY; EVIDENCE BASED PRACTICE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE; HEALTH CARE ACCESS; HEALTH CARE COST; HUMAN; MEDICAL CARE; PATENT; PATIENT SAFETY; PRACTICE GUIDELINE; PSORIASIS; DRUG APPROVAL; DRUG LEGISLATION; EUROPE; LEGISLATION AND JURISPRUDENCE; UNITED STATES;

BIOSIMILAR PHARMACEUTICALS; DERMATOLOGIC AGENTS; DRUG APPROVAL; EUROPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEGISLATION, DRUG; PSORIASIS; UNITED STATES;

EID: 84898769627     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/ddg.12294_suppl     Document Type: Article

References (46)

1. Nast A, Boehncke WH, Mrowietz U et al. Deutsche Dermatologische Gesellschaft (DDG); Berufsverband Deutscher Dermatologen (BVDD). S3-Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges 2012; 10: S1-95.
2. Augustin M, Glaeske G, Schäfer I et al. Processes of psoriasis health care in Germany - long-term analysis of data from the statutory health insurances. J Dtsch Dermatol Ges 2012; 10(9): 648-55.
3. Tsiftsoglou AS, Ruiz S, Schneider CK. Development and regulation of biosimilars: current status and future challenges. BioDrugs 2013; 27(3): 203-11.
4. Schellekens H. How similar do "biosimilars" need to be? Nat Biotechnol 2004; 22: 1357-9.
5. Subramanyam M. Clinical development of biosimilars: an evolving landscape. Bioanalysis 2013; 5(5): 575-86.
6. Schellekens H. Biosimilar therapeutics-what do we need to consider? NDT Plus 2009; 2: 27-36.
7. Dörner T, Strand V, Castañeda-Hernández G et al. The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 2013; 72(3): 322-8.
8. Augustin M, Krüger K, Radtke MA et al. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 2008; 216: 366-72.
9. Radtke MA, Schäfer I, Blome C et al. Patient Benefit Index (PBI) in the treatment of psoriasis - results of the National Care Study "PsoHealth". Eur J Dermatol 2013; 23: 212-7.
10. Declerck PJ. Biosimilar monoclonal antibodies: a science-based regulatory challenge. Expert Opin Biol Ther 2013; 13: 153-6.
11. Desanvicente-Celis Z, Gomez-Lopez A, Anaya JM. Similar biotherapeutic products: overview and reflections. Immunotherapy 2012; 4: 1841-57.
12. Ebbers HC, Pieters T, Leufkens HG et al. Effective pharmaceutical regulations needs alignment with doctors. Drug Discov Today 2012; 17: 100-3.
13. Fleischmann R, Shealy D. Developing a new generation of TNFalpha antagonists for the treatment of rheumatoid arthritis. Mol Interv 2003; 3: 310-8.
14. Efalizumab: anti-CD11a monoclonal antibody-Genentech/ Xoma, HU 1124, hu1124, xanelim. Drugs R D 2002; 3: 40-3.
15. Gershon SK, Luksenburg H, Coté TR et al. Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med 2004; 351: 1403-8.
16. Strand V, Kimberley R, Isaacs JD. Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov 2007; 6: 75-92.
17. Schellekens H: Biosimilar therapeutic agents: issues with bioequivalence and immunogenicity. Eur J Clin Invest 2004; 34: 797-9.
18. Atzeni F, Talotta R, Benucci M et al. Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev 2013; 12: 703-8.
19. Ramos-Casals M, Brito-Zerón P, Munoz S et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine 2007; 86: 242-51.
20. Roger SD, Milkhail A. Biosimilars: opportunity or cause for concern? J Pharm Pharm Sci 2007; 10: 405-10.
21. Subramanyam M. Clinical development of biosimilars: an evolving landscape. Bioanalysis. 2013; 5: 575-86.
22. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 2002; 1: 457-62.
23. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol 2008; 19: 411-9.
24. Chrino AJ, Mire-Sluis A. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol 2004; 22: 1383-91.
25. Jefferis R. Glycosylation as a strategy to improve amtibodybased therapeutics. Nat Rev Drug Discov 2009; 8: 226-34.
26. Jahn EM, Schneider CK. How to systemically evaluate immunogenicity of therapeutic proteins-regulatory considerations. N Biotechnol 2009; 25: 280-6.
27. Brockmeyer C, Seidl A. Binocrit: Assessment of quality, safety and efficacy of biopharmaceuticals. EJHP Practice 2009; 15: 38-44.
28. Sterry W, vande Kerkhof P. Is "class effect" relevant when assessing the benefit/risk profile of a biologic agent? J Eur Acad Derm 2012; 26 Suppl 5: 9-16.
29. Strober BE, Armour K, Romiti R et al. Biopharmaceuticals and biosimilars in psoriasis: What the dermatologist needs to know. J Am Acad Dermatol 2012; 66: 317-22.
30. Augustin M, Spehr C, Radtke MA et al. Deutsches Psoriasis-Register PsoBest: Zielsetzung, Methodik und Basisdaten. J Dtsch Dermatol Ges 2014; 12(1): 48-58.
31. Papp KA, Strober B, Augustin M et al. PSOLAR investigators and Steering Committee. PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. J Drugs Dermatol 2012; 11(10): 1210-7.
32. Ormerod AD, Augustin M, Baker C et al. Challenges for synthesising data in a network of registries for systemic psoriasis therapies. Dermatology 2012; 224(3): 236-43.
33. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. 2006.
34. European Medicines Agency, Committee for Medicinal products for Human Use (CHMP): Guideline on similar biological medicinal products. CHMP/437/04. London, 30 October 2005.
35. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP): Draft: Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. EMA/CHMP/BMWP/14327/2006. London, 24 January 2007.
36. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP): Guideline on comparability of biotechnology-derived medicinal products after a change in the manufacturing process. Non-clinical and clinical issues. EMA/CHMP/BMWP/101695/2006. London, 19 July 2007.
37. European Medicines Agency, Committee for Medicinal Products for uman Use (CHMP): Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: Non-clinical and clinical issues. EMA/CHMP/BMWP/42832/2005. London, 22 February 2006.
38. European Medicines Agency. Questions and answers on biosimilar medicines (similar biological medicinal products). 27-9-2012, 18-11-2012.
39. Lee H, Yim DS, Zhou H et al. Evidence of effectiveness: how much can we extrapolate from existing studies? AAPS J 2005; 7: E467-74.
40. §129 Abs.1 und 2 des Fünften Buches Sozialgesetzbuch (SGB V) in Verbindung mit dem Rahmenvertrag über die Arzneimittelversorgung nach §129 Abs. 2 SGB V zwischen GKV-Spitzenverband und dem Deutschen Apothekerverband e.V. in der Fassung vom 01.02.2011.
41. Romer T, Zabransky M, Walczak M. Effect of switching recombinant human growth hormone: Comparative analysis of phase 3 clinical data. Biol Ther 2011; 1: 5.
42. Korswagen LA, Bartelds GM, Krieckaert CL et al. Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study. Arthritis Rheum 2011; 63: 877-83.
43. Ebbers HC, Crow SA, Vulto AG et al. Interchangeability, immunogenicity and biosimilars. Nat Biotechnol 2012; 30: 1186-90.
44. Colbert RA, Cronstein BN. Biosimilars: the debate continues. Arthritis Rheum 2011; 63: 2848-50.
45. Joshi SR. Biosimilar peptides: need for pharmacovigilance. J Assoc Physicians India 2011; 59: 44-7.
46. Casadevall N, Edwards IR, Felix T et al. Pharmacovigilance and biosimilars: comsiderations, needs and challenges. Expert Opin Biol Ther 2013; 13(7): 1039-47.